PBAE Polymer Nanoparticles for Lung-Specific mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mRNA delivery technologies face challenges in achieving potent, specific delivery to non-liver tissues, particularly the lungs, due to barriers such as RNAse-mediated degradation, cellular entry, and endosomal escape, limiting the broad clinical realization of RNA therapeutics.
Innovation Solution
A polymer of Formula (I) is developed, which forms a nanoparticle composition with a PEG lipid, steroid, and mRNA, optimized for lung-specific delivery, enhancing the molar ratio of A:B and incorporating alkyl substituents for improved cellular uptake and tissue specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional mRNA delivery methods are used, then delivery to liver tissue is achieved, but delivery to non-liver tissues (particularly lungs) is insufficient
Solution Approach 1:
The patent applies local quality by incorporating a cholesterol moiety into the polymer structure to specifically enhance interaction with lung tissue components. The polymer is designed with distinct functional regions: a cationic segment for mRNA binding, a cholesterol segment for membrane interaction and lung tissue affinity, and a hydrophilic segment for stability. This localized functional differentiation enables selective accumulation and delivery to lung tissue while maintaining efficient mRNA complexation.
2Productivity
If polymer composition is optimized for cellular uptake, then transfection efficiency improves, but RNAse-mediated degradation increases
Solution Approach 1:
The patent employs the cholesterol moiety as an intermediary that mediates between the cationic polymer segment and the cellular membrane. The cholesterol acts as a hydrophobic bridge that facilitates membrane penetration and endosomal escape while protecting the mRNA from RNAse degradation. This intermediary function enables efficient cellular uptake and transfection without compromising mRNA stability, as the cholesterol shield prevents enzymatic access to the nucleic acid.
3Reliability
If polymer molecular weight is increased to enhance nanoparticle formation, then delivery potency increases, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the polymer into three distinct repeat units that can be independently synthesized and then assembled through step-growth polymerization. This modular architecture allows each segment (cationic, cholesterol-containing, and hydrophilic) to be optimized separately and then combined in controlled ratios. The segmented approach simplifies manufacturing by enabling precise control over molecular weight and composition through stoichiometric mixing of pre-synthesized monomers, rather than requiring complex one-step polymerization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer-based nanoparticle composition achieves significantly higher mRNA delivery efficacy to lung tissues compared to existing methods, demonstrating orders of magnitude more potency and specificity, as evidenced by luciferase signal and transfection efficiency in mouse models.
Implementation Method 1
A polymer of Formula (I) is developed, which forms a nanoparticle composition with a PEG lipid, steroid, and mRNA
Data Source
AI summary
The present disclosure relates to improvements in the selection and formulation of PBAE polymers using a design of experiment approach, in which statistical methods are used to limit possible experimental conditions. The present disclosure relates to improved PBAE polymers and formulations.